Recently, the Gray group developed a kinase inhibitor targeting Leucine-rich repeat kinase 2 (LRRK2), which is implicated in both genetically predisposed and sporadic Parkinson’s disease[16]. The gene discussed is LRRK2; the disease is Parkinson disease.